NeuroPhage Pharmaceuticals, Inc., a Cambridge, MA-based developer of therapies for neurodegenerative diseases, raised $6.4m in equity financing.
Founded in 2007 and led by Jonathan Solomon, President and Chief Executive Officer, NeuroPhage is a biotechnology company that advances the treatment of chronic neurodegenerative diseases associated with protein misfolding, including Alzheimer’s and Parkinson’s diseases. It is applying its technology platform to develop a pipeline of drug candidates consisting of broadly acting agents that simultaneously reduce levels of multiple pathogenic protein aggregates in the brain.
NeuroPhage intends to use the funds for ongoing pre-IND studies for lead compound NPT002 and advancement of fusion proteins for treating neurodegenerative conditions including Alzheimer’s, Parkinson’s and Huntington’s diseases.
In addition to the funding, Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director.